In brief: the numbers that change the rules of the game
According to the analytical system PharmXplorer (Proxima Research) and the weekly magazine “Apteka”, the share of Ukrainian-made products in pharmacy sales fell from 57.6% in 2024 to 55.2% in 2025. The market trend — more imports in value and in physical structure — is occurring simultaneously with growth in total sales.
What happened and why it matters
Total pharmacy sales in 2025 grew by 14% to 221.9 billion UAH (in dollar terms +9.8% — $5.3 billion). However, in physical terms sales decreased by 2.1% — to 1.3 billion packages. In other words, the market’s value is rising driven by more expensive categories and exchange-rate factors, while physical volumes are falling.
Where the space for imports opens up
The key driver is the dietary supplements segment, which shows the highest growth rates: +24.8% in value and +3.4% in volumes. Supplements’ share of the market structure amounted to 12.3% in value and 9.5% in physical terms. This raises the market’s average price per package: supplements — 227 UAH, medicines — 213.5 UAH, cosmetics — 182.4 UAH, medical devices — 47.1 UAH.
Competition and availability issues
The Antimonopoly Committee of Ukraine (АМКУ) in October 2025 opened a case against the five largest pharmacy chains (АНЦ, «Доброго дня», «9-1-1», «Подорожник», «Бажаємо здоров’я»), which control 64% of retail turnover and own 42% of pharmacy outlets. The case states that since February 2025 the availability of medicines from three Ukrainian manufacturers has decreased in pharmacies despite stable demand.
"The reduction in the number of medicines from three Ukrainian manufacturers, despite stable demand, may indicate deliberate restriction of sales of certain medicines, which contradicts the law on protection of economic competition."
— Antimonopoly Committee of Ukraine
Government response and market consequences
In mid‑January 2026 the Cabinet of Ministers instructed the Ministry of Health and the State Service for Food Safety and Consumer Protection to tighten control over pharmacy prices and monitor compliance with mark‑ups. This is a direct response to the risk that rising imports and market concentration create a threat to availability and higher prices for the end consumer.
What this means for patients and the industry
For the patient: the cost of treatment may rise or become less predictable if the supply of cheaper domestic medicines narrows. For pharma: a decline in share within the pharmacy network is a signal to review distribution channels, pricing policy and cooperation with the state to maintain shelf presence and ensure hospitals and pharmacies receive the necessary assortment.
Brief forecast
If state control and antimonopoly investigations lead to a restoration of competition, the share of domestic manufacturers may stabilize. Otherwise there is a risk of deepening import dependence and job losses in pharma. This is not just a market issue: it is a question of national economic resilience and access to medical care.
Sources: PharmXplorer (Proxima Research), weekly magazine “Apteka”, statements from the Antimonopoly Committee of Ukraine, Cabinet of Ministers decisions (January 2026).
